Mumbai April 4 (IANS) Global pharmaceutical company Cipla on Tuesday announced that it has received final approval of the US Food and Drug Administration (USFDA) for the generic version of Epzicom tablets -- for the treatment of HIV-1 infection.
Abacavir and Lamivudine Tablets USP 600 mg/300 mg are AB-rated generic equivalents to the reference listed drug (RLD) Epzicom Tablets 600 mg/300 mg of ViiV Healthcare Company and are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection the company said in a statement.
The product will cater to the US market and will be commercially available shortly it added.
According to IMS Health -- the American firm that provides information services and technology for the healthcare industry -- Epzicom tablets had US sales of approximately $346.3 million for the 12-month period ending February.
--IANS
ppg/in/dg
Cipla gets US regulatory nod for generic Epzicom tablets
